Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12291840 | 0.79 | KIF11 (0.47) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4023529 | 0.79 | NR4A1 (0.59) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2575608 | 0.79 | NR4A1 (0.59) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4023527 | 0.79 | NR4A1 (0.59) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL313169 | 0.77 | KIF11 (0.75) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1474242 | 0.77 | KIF11 (0.56) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL14099337 | 0.71 | KIF11 (0.49) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29620952 | 0.71 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL850429 | 0.71 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL19136587 | 0.70 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | KIF11 2259/4885KCNQ3 234/4885KCNQ2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.